These data indicate that EVs can promote responsiveness in a tumor that is initially insensitive to anti–PD-1/anti–PD-L1 treatment, making treatment with EVs and anti–PD-1/anti–PD-L1 combination a promising strategy for the clinic. This evidence concerns the gene CD274 and neoplasm.